PDF icon PDF herunterladen
Aktuelle Rheumatologie 2008; 33(6): 325-336
DOI: 10.1055/s-2007-963741
Übersichtsarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Prognose des primären Sjögren-Syndroms unter besonderer Berücksichtigung des Lymphomrisikos

Prognosis of Primary Sjögren’s Syndrome with Special Regard to the Risk of LymphomaC. Tomiak1
  • 1Reha-Zentrum Bad Aibling der Deutschen Rentenversicherung Bund, Klinik Wendelstein, Rheumazentrum – AHB-Klinik
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Dezember 2008 (online)

Auch verfügbar aufeRef
   Lizenzen und Reprints
Preview

Zusammenfassung

Das primäre Sjögren-Syndrom ist eine chronische Autoimmunepithelitis, die Speichel-, Tränen- und andere exokrine Drüsen befällt. Extraglanduläre Manifestationen sind häufig, jedoch selten bedrohlich. Die Sicca-Symptomatik ist häufig chronisch progredient, wobei die Progredienz am stärksten im Zeitraum von der Erstmanifestation bis zur Diagnosestellung zu sein scheint. Das klinische Gesamtbild wie auch die individuelle serologische Konstellation einschließlich der Manifestationen ist sehr variabel und hat sich in Langzeituntersuchungen vom Zeitpunkt der Diagnosestellung an als sehr stabil erwiesen, sie verändern sich kaum im Vergleich zum Zeitpunkt der Diagnosestellung. Letzteres erlaubt möglicherweise eine Risikoabschätzung bereits bei Diagnosestellung. Die Lebenserwartung der Erkrankten ist mit Ausnahme einer kleinen Patientengruppe nicht reduziert. Das primäre Sjögren-Syndrom prädisponiert mehr als alle anderen Kollagenosen zu Malignomen des hämatopoetischen Systems, insbesondere treten gehäuft Non-Hodgkin-Lymphome auf. Die vorliegende Arbeit beleuchtet unterschiedliche Aspekte des Langzeitverlaufs im Hinblick auf Prognose, Lebenserwartung und Lymphomgefährdung. Daraus abgeleitet werden eine Risikoeinschätzung und die resultierende Intensität der Langzeitüberwachung der Patienten vorgeschlagen.

Abstract

Primary Sjögren’s syndrome is a chronic autoimmune epithelitis which affects salivary, lacrimal and other exocrine glands. Extraglandular manifestations are common but seldom dangerous and threatening. The sicca symptoms are often slowly chronic-progressive whereby the progress seems to be most striking during the period between first manifestation and confirmation of diagnosis. The clinical course as well as the serological constellations and the extraglandular manifestations seem to be rather variable but stable during the long-term follow-up from the time of diagnostic confirmation onwards with no drastic changes compared with the status when the diagnosis was fixed. This probably allows an initial prognostic stratification at the time of the first consultation. The life expectancy of patients with Sjögren’s syndrome is, except for a minority of patients, as good as that of the age-adjusted population. In comparison with other collagen diseases, the predisposition for the development of non-Hodgkin’s lymphoma is strikingly high in primary Sjögren’s syndrome. This paper discusses different aspects of prognosis with special consideration of the life expectancy and lymphoma development. Finally, a practical mode of long-term medical care for patients with Sjögren’s syndrome is proposed with special regard to risk stratification and intensity of long-term monitoring.

Schlüsselwörter

Sjögren-Syndrom - Lymphom - Prognose - Lymphomscreening - Exokrine Funktion

Key words

Sjögren’s syndrome - lymphoma - prognosis - screening for lymphoma - exocrine function

Literatur

  • 1 Aasarod K, Haga H J, Berg K J. et al . Renal involvement in primary Sjögren’s syndrome.  QJM. 2000;  93 297-304
    Suche in Google Scholar
  • 2 Abu-Shakra M, Buskila D, Ehrenfeld M. et al . Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.  Ann Rheum Dis. 2001;  60 433-441
    Suche in Google Scholar
  • 3 Aljurf M D, Owaidah T W, Ezzat A. et al . Antigen- and ord immune-driven lymphoproliferative disorders.  Annals of Oncology. 2003;  14 1595-1606
    Suche in Google Scholar
  • 4 Amft N, Bowman S J. Chemokines and Cell Trafficking in Sjögren’s Syndrome.  Scand J Immunol. 2001;  54 62-69
    Suche in Google Scholar
  • 5 Bahler D W, Miklos J A, Swerdlow S H. Ongoing Ig gene hypermutation in salivary mucosa-associated lymphoid tissue type lymphomas.  Blood. 1997;  89 3335-3344
    Suche in Google Scholar
  • 6 Bernatsky S, Ramsey-Goldman R, Clarke A. Malignancy and autoimmunity.  Curr Opin Rheumatol. 2006;  18 (2) 129-134
    Suche in Google Scholar
  • 7 Binder A, Snaith M L, Isenberg D. Sjögren’s syndrome: a study of its neurological complications.  Br J Rheumatol. 1988;  27 275-280
    Suche in Google Scholar
  • 8 Bossini N, Savoldi S, Franceschini F. et al . Clinical and morphological features of kidney involvement in primary Sjögren’s syndrome.  Nephrol Dial Transplant. 2001;  16 2328-2236
    Suche in Google Scholar
  • 9 Chiu C H, Weisenburger D D. An update of the epidemiology of Non-Hodgkin’s lymphoma.  Clinical Lymphoma. 2003;  4 161-168
    Suche in Google Scholar
  • 10 Davidson B K, Kelly C A, Griffiths I D. Primary Sjogren’s syndrome in the North East of England: a long-term follow-up study.  Rheumatology. 1999;  38 (3) 245-253
    Suche in Google Scholar
  • 11 Devauchell-Pensec V, Pennec Y, Morvan J. et al . Improvement of Sjögren’s syndrome after two infusions of Rituximab (anti-CD 20).  Arthritis Care & Research. 2007;  57 310-317
    Suche in Google Scholar
  • 12 Ekström Smedby K, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.  Cancer Epidemiol Biomarkers Prev. 2006;  15 (11) 2069-2077
    Suche in Google Scholar
  • 13 Ekström-Smedby K, Hjalgrim H, Askling J. et al . Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.  J Natl Cancer Inst. 2006;  98 (1) 51-60
    Suche in Google Scholar
  • 14 Franquet T, Díaz C, Domingo P. et al . Air trapping in primary Sjögren’s syndrome: correlation of expiratory CT with pulmonary function tests.  J Comput Assist Tomogr. 1999;  23 169-173
    Suche in Google Scholar
  • 15 Gannot G, Lancaster H E, Fox P C. Clinical course of primary Sjogren’s syndrome: salivary, oral and serological aspects.  J Rheumatol. 2000;  27 1905-1909
    Suche in Google Scholar
  • 16 Garcia-Carrasco M, Siso A, Ramos-Casals M. et al . Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients.  J Rheumatol. 2002;  29 726-730
    Suche in Google Scholar
  • 17 Gasparotto D, De Vita S, De Re V. et al . Extrasalivary lymphoma development in Sjögren’s syndrome: Clonal evolution from parotid gland lymphoproliferation and role of local triggering.  Arthritis Rheum. 2003;  48 (11) 3181-3186
    Suche in Google Scholar
  • 18 Goules A, Masouridi S, Tzioufas A G. et al . Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome.  Medicine (Baltimore). 2000;  79 241-249
    Suche in Google Scholar
  • 19 Haldorsen K, Moen K, Jacobsen H. et al . Exocrine function in primary Sjögren’s syndrom. Natural course and prognostic factors.  Ann Rheum Dis Online First. 2007;  DOI: 10.1136 /ard.2007.074203
    Suche in Google Scholar
  • 20 Hansen A, Reiter K, Pruss A. et al . Dissemination of a Sjogre’s syndrome associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements.  Arthritis Rheum. 2006;  54 (1) 127-137
    Suche in Google Scholar
  • 21 Harris N L, Jaffe E S, Diebold J. et al . The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.  Histopathology. 2000;  36 (1) 69-86
    Suche in Google Scholar
  • 22 Harris N L. Lymphoid proliferation of the salivary glands.  Am J Clin Pathol. 1999;  111 (1 Suppl 1) S94-S103
    Suche in Google Scholar
  • 23 Hoover R N. Lymphom risk in populations with altered immunity – a search for mechanisms.  Cancer Res. 1992;  52 (Suppl 19) 5477 s-5478 s
    Suche in Google Scholar
  • 24 Ioannidis J P, Vassiliou V A, Moutsopoulos H M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome.  Arthritis Rheum. 2002;  46 (3) 741-747
    Suche in Google Scholar
  • 25 Jaffe E S. Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis.  Am J Clin Pathol. 2002;  15 255-263
    Suche in Google Scholar
  • 26 Jonnson R, Kroneld U, Backman K. et al . Progression of sialadinitis in Sjogren’s syndrome.  Br J Rheumatol. 1993;  32 578-581
    Suche in Google Scholar
  • 27 Kaplan M J, Ike R W. The liver is common non-exocrine target in primary Sjögren’s syndrome. A retrospective review.  BMC Gastroenterology. 2002;  2 21-29
    Suche in Google Scholar
  • 28 Kassan S S, Thomas T L, Moutsopoulos H M. et al . Increased risk of lymphoma in sicca syndrome.  Ann Intern Med. 1978;  89 888-892
    Suche in Google Scholar
  • 29 Kauppi M, Pukkala E, Isomäki H. Elevated incidence of hematologic malignancies in patients with Sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland).  Cancer Causes and Control. 1997;  8 201-204
    Suche in Google Scholar
  • 30 Kruize A A, Bijsterveld O P, Hené R J. et al . Long term course of tear gland function in patients with keratoconjunctivitis sicca and Sjögren’s syndrome.  British Journal of Ophthalmology. 1997;  81 435-438
    Suche in Google Scholar
  • 31 Leandro M J, Isenberg D A. Rheumatic disease and malignancy – is there an association?.  Scand J Rheum. 2001;  30 185-188
    Suche in Google Scholar
  • 32 Lodde B M, Sankar van V, Kok M R. et al . Serum lipid levels in Sjögren’s syndrome.  Rheumatology. 2006;  45 481-484
    Suche in Google Scholar
  • 33 Looney R J. Will targeting B cells be the answer for Sjogren’s syndrome?.  Arthritis Rheum. 2007;  56 1371-1377
    Suche in Google Scholar
  • 34 Lopate G, Pestronk A, Al-Lozi M. et al . Peripheral neuropathy in an outpatient cohort of patients with Sjögren’s syndrome.  Muscle Nerve. 2006;  33 672-676
    Suche in Google Scholar
  • 35 Manthorpe R, Manthorpe T. Das primäre Sjögren-Syndrom – Epidemiologie und Prognose.  Akt Rheumatol. 2005;  30 27-31
    Suche in Google Scholar
  • 36 Manthorpe R. Wie klassifizieren wir Patienten, bei denen wir ein Sjögren-Syndrom vermuten?.  Akt Rheumatol. 2005;  30 32-37
    Suche in Google Scholar
  • 37 Mariette X. Lymphomas in patients with Sjogren’s syndrome: review of the literature and physiopathologic hypothesis.  Leuk Lymphoma. 1999;  33 (1-2) 93-99
    Suche in Google Scholar
  • 38 Martens P B, Pillemer S R, Jacobson L T. et al . Survivorship in a population based cohort of patients with Sjogren’s syndrome, 1976-1992.  J Rheumatol. 1999;  26 (6) 1296-1300
    Suche in Google Scholar
  • 39 Masaki Y, Sugai S. Lymphoproliferative disorder in Sjögren’s syndrome.  Autoimmunity Review. 2004;  3 175-182
    Suche in Google Scholar
  • 40 Mori K, Iijima M, Koike H. et al . The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy.  Brain. 2005;  128 2518-2534
    Suche in Google Scholar
  • 41 Moutsopoulos H M, Andonopoulos A P. Sjögren’s syndrome: a human model of autoimmunity and malignancy.  Rheumatology. 1988;  27 253-257
    Suche in Google Scholar
  • 42 National Cancer Institute . Adult Non-Hodgkin’s Lymphoma Treatment (PDQ®):.  , (http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional/allpages); letzte Modifikation 11.2.2007
  • 43 Ognenovski V M, Marder W, Somers E C. et al . Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophasphaide.  J Rheum. 2004;  31 1763-1767
    Suche in Google Scholar
  • 44 Papiris S A, Maniati M, Constantopoulos S H. Lung involvement in primary Sjögren’s syndrome is mainly related to the small airway disease.  Ann Rheum Dis. 1999;  58 61-64
    Suche in Google Scholar
  • 45 Pertovaara M, Korpela M, Kouri T. et al . The occurrence of renal involvement in primary Sjögren’s syndrome: a study of 78 patients.  Rheumatology. 1999;  38 1113-1120
    Suche in Google Scholar
  • 46 Pertovaara M, Korpela M, Kouri T. et al . The occurrence of renal involvement in primary Sjögren’s syndrome: a study of 78 patients.  Rheumatology. 1999;  38 1113-1120
    Suche in Google Scholar
  • 47 Pertovaara M, Korpela M, Saarelainen S. et al . Long-term follow-up study of pulmonary findings in patients with primary Sjögren’s syndrome.  Scand J Rheumatol. 2004;  33 343-348
    Suche in Google Scholar
  • 48 Pertovaara M, Korpela M, Uusitalo H. et al . Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).  Ann Rheum Dis. 1999;  58 423-427
    Suche in Google Scholar
  • 49 Pijpe J, Kalk W W, Bootsma H. et al . Progression of salivary gland dysfunction in patients with Sjogren’s syndrome.  Ann Rheum Dis. 2007;  66 107-112
    Suche in Google Scholar
  • 50 Pijpe J, Imhoff G W, Vissink van A. et al . Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma.  Ann Rheum Dis. 2005;  64 958-960
    Suche in Google Scholar
  • 51 Plesivcnik Novljan M, Rozman B, Hocevar A. et al . Incidence of primary Sjögren’s syndrome in Slovenia.  Ann Rheum Dis. 2004;  63 874-876
    Suche in Google Scholar
  • 52 Plessivcnik Novljan M, Rozman B, Jerše M. et al . Comparison of the different classification criteria set for primary Sjögren’s syndrome.  Scand J Rheumatol. 2006;  6 463-467
    Suche in Google Scholar
  • 53 Ramos-Casals M, Anaya J M, García-Carrasco M. et al . Cutaneous vasculitis in primary Sjögren syndrome. Classification and clinical significance of 52 patients.  Medicine. 2004;  83 96-106
    Suche in Google Scholar
  • 54 Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren’s syndrome.  Rheumatology. 2007;  46 1389-1396
    Suche in Google Scholar
  • 55 Ramos-Casals M, De Vita S, Tzioufas A G. Hepatitis C virus, Sjögren’s syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer.  Autoimmun Rev. 2005;  4 (1) 8-15
    Suche in Google Scholar
  • 56 Ramos-Casals M, Font J, Garcia-Carrasco M. et al . Primary Sjögren syndrome: hematologic patterns of disease expression.  Medicine. 2002;  81 281-292
    Suche in Google Scholar
  • 57 Ramos-Casals M, Tsioufas A G, Font G. Primary Sjögren’s syndrom: new clinical and therapeutic concepts.  Ann Rheum Dis. 2005;  64 347-354
    Suche in Google Scholar
  • 58 Rogers S J, Williams C S, Romám G C. Myelopathy in Sjögren’s syndrome.  Drugs. 2004;  64 123-132
    Suche in Google Scholar
  • 59 Salomonsson S, Jonsson M V, Skarstein K. et al . Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome.  Arthritis Rheum. 2003;  48 (11) 3187-3201
    Suche in Google Scholar
  • 60 Seror R, Sordet C, Guillevin L. et al . Tolerance and efficacy of Rituximab and changes in serum B cell biomarkers in patients mit systemic complications of primary Sjögren’s syndrome.  Ann Rheum Dis. 2007;  66 351-357
    Suche in Google Scholar
  • 61 Seve P, Gachon E, Petiot P. et al . Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren’s syndrome.  Rheumatol Int. 2007;  28 175-177
    Suche in Google Scholar
  • 62 Skopouli F N, Dafni U, Ioannidis J P. et al . Clinical evaluation, and morbidity and mortality of primary Sjögren’s syndrome.  Semin Arthritis Rheum. 2000;  29 467-472
    Suche in Google Scholar
  • 63 Skoupouli F N. Kidney injury in Sjögren’s syndrome.  Nephrol Dial Transplant. 2001;  16 (Suppl 6) 63-64
    Suche in Google Scholar
  • 64 Sugai S, Masaki Y, Dong L. Lymphoproliferative disorders in patients with Sjögren’s syndrome.  Autoimmun Rev. 2004;  3 (Suppl 1) S67-S69
    Suche in Google Scholar
  • 65 Sutcliffe N, Inanc M, Speight P. et al . Predictors of Lymphoma development in primary Sjögren’s syndrome.  Semin Arthritis Rheum. 1998;  28 (2) 80-87
    Suche in Google Scholar
  • 66 Talal N, Bunim J J. The development of malignant lymphoma in the course of Sjögren’s syndrome.  Am J Med. 1964;  36 529-540
    Suche in Google Scholar
  • 67 Thanou-Stavraki A, James J A. Primary Sjogren’s Syndrome: Current and prospective therapies.  Semin Arthritis Rheum. 2007;  (ahead of print) DOI: 10.1016 /j.semarthrit.2007.06.002
    Suche in Google Scholar
  • 68 Theander E, Andersson S I, Manthorpe R. et al . Proposed core set of outcome measures in patients with primary Sjogren’s syndrome: 5 years follow up.  J Rheumatol. 2005;  32 1495-1502
    Suche in Google Scholar
  • 69 Theander E, Henriksson G, Ljungberg O. et al . Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors.  Ann Rheum Dis. 2006;  65 796-803
    Suche in Google Scholar
  • 70 Theander E, Manthorpe R, Jacobsson L TH. Mortality and causes of death in primary Sjögren’s syndrome.  Arthritis Rheum. 2004;  50 (4) 1262-1269
    Suche in Google Scholar
  • 71 Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren’s syndrome with Rituximab.  Scand J Rheumatol. 2006;  35 323-325
    Suche in Google Scholar
  • 72 Tzioufas A G, Katisikis P D, Youinou P Y. et al . Sjogren’s syndrome: an oligoclonal B cell process.  Clin Exp Rheumatol. 1990;  8 (Suppl 5) 17-21
    Suche in Google Scholar
  • 73 Vaudo G, Bartoni Bocci E, Shoenfeld Y. et al . Precocious intima-media thickening in patients with primary Sjögren’s syndrome.  Arthritis Rheum. 2005;  52 (12) 3890-3897
    Suche in Google Scholar
  • 74 Voulgarelis M, Dafni U, Isenberg D I. et al . Malignant lymphoma in primary Sjögren’s syndrome.  Arthritis Rheum. 1999;  42 1765-1772
    Suche in Google Scholar
  • 75 Voulgarelis M, Giannouli S, Anagnostou D. et al . Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas.  Hematology. 2004;  43 1050-1053
    Suche in Google Scholar
  • 76 Voulgarelis M, Gianouli S, Tzioufas A G. et al . Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, predinisone).  Ann Rheum Dis. 2006;  65 (8) 1033-1037
    Suche in Google Scholar
  • 77 Yamout B, El-Hajj T, Barada W. et al . Successful treatment of refractory neuroSjogren with Rituximab.  Lupus. 2007;  16 521-523
    Suche in Google Scholar
  • 78 Zintzaras E, Voulgarelis M, Moutsopoulos H M. The risk of lymphoma development in autoimmune diseases: a meta-analysis.  Arch Intern Med. 2005;  165 (20) 2337-2344
    Suche in Google Scholar

Dr. Christian Tomiak

Reha-Zentrum Bad Aibling der Deutschen Rentenversicherung Bund, Klinik Wendelstein, Rheumazentrum – AHB-Klinik,

Kolbermoorerstr. 56

83043 Bad Aibling

Telefon: ++ 49/80 61/2 71 64

Fax: ++ 49/80 61/2 71 82

eMail: Drmed. Christian.Tomiak@drv-bund.de